Ipamorelin
Growth hormone secretagogue · 5 amino acids
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels.
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels.
Mechanism of Action
Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a) located in the pituitary gland and hypothalamus.
When Ipamorelin binds to GHS-R1a, it stimulates the release of stored growth hormone from somatotroph cells in a pulsatile manner that mimics the body's natural GH secretion pattern.
What distinguishes Ipamorelin from earlier GHS compounds (GHRP-6, GHRP-2) is its selectivity. While GHRP-6 causes significant cortisol and prolactin release, Ipamorelin selectively stimulates GH release with minimal impact on cortisol, prolactin, or appetite.
Reported Effects
Commonly Reported
- Increased growth hormone secretion in a dose-dependent manner in animal models
- Improved body composition (increased lean mass, decreased fat mass) in rodent studies
- Enhanced recovery from exercise-induced tissue damage in animal models
- Improved sleep architecture in some animal studies
Less Common Reports
- Anti-aging effects on skin and connective tissue in rodent models
- Bone density improvements in osteoporosis models
- Potential neuroprotective effects
- Mild improvement in immune function markers
All reported effects originate from pre-clinical research.
Optimizing growth hormone release during natural sleep cycles
Side Effects & Safety Profile
Low Concern
- Mild injection site reactions
- Water retention at higher doses
- Occasional tingling sensation
Moderate Concern
- Potential for GH-related side effects at sustained high doses
- Long-term safety profile unknown in humans
- Possible insulin sensitivity changes (dose-dependent)
Serious
- No serious adverse events reported in available pre-clinical literature
- Theoretical risk of promoting growth of pre-existing neoplasms (GH-mediated)
- Source purity is a significant variable
Clinical Evidence
Research on Ipamorelin has been primarily pre-clinical:
- Dose-response studies — Demonstrated selective GH release without significant cortisol or prolactin elevation
- Body composition studies — Rodent models showing improved lean mass and reduced fat mass
- Bone health — Studies in ovariectomized rat models of osteoporosis showing improved bone mineral density
- Recovery — Accelerated healing in rodent soft tissue injury models
No human clinical trials have been registered.
Discovery Timeline
- 1998 — Ipamorelin developed by Novo Nordisk as a selective GHS
- 2000s — Pre-clinical characterization of selective GH release properties
- 2005–2010 — Research on body composition and bone density effects
- 2010s — Growing interest as a cleaner GHS option
- 2020–present — Continued pre-clinical research
Enhanced recovery and lean muscle development
Community Research Notes
The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.
"The most boring peptide I take, but I keep taking it because my sleep scores went up 20 percent and my recovery data improved noticeably." — r/Peptides user
"It works quietly. The evidence shows up in data and long-term trends, not in subjective sensations." — r/Peptides user
"No hunger spike, no flushing, no mood change — just background improvements in sleep and recovery that compound over time." — r/Biohackers user
Frequently Asked Questions
Is ipamorelin safe? Ipamorelin has a strong safety profile in available research. The selectivity that prevents cortisol and prolactin spikes also reduces the risk of side effects. It is considered one of the safest GH secretagogues.
How is ipamorelin different from GHRP-6? Both are GH secretagogues that work through the ghrelin receptor. GHRP-6 causes significant hunger and cortisol spikes. Ipamorelin does neither. It is a more selective, cleaner compound.
What is the typical research dose? Common protocols use 200 to 300 mcg administered 2 to 3 times daily. Bedtime dosing is common to align with natural GH release during sleep.
How long before results appear? Sleep improvements can appear within the first week. Body composition and recovery benefits typically take 8 to 12 weeks of consistent use.
Can ipamorelin be used alone? Yes, but it is most effective when combined with a GHRH peptide like CJC-1295 or sermorelin. The combination produces a larger GH release than either peptide alone.
Compounds That Pair Well
- CJC-1295 (without DAC) — The classic CJC/Ipamorelin stack. CJC-1295 provides sustained GHRH stimulation; ipamorelin provides the ghrelin-receptor pulse. Together they produce a larger, longer GH release than either compound alone.
- Sermorelin — An alternative to CJC-1295 for GHRH stimulation with a shorter half-life, suitable for those preferring a more transient release pattern.
- Tesamorelin — Combined GHRH pathway activation with ipamorelin's ghrelin-receptor pulse for enhanced GH output.
- BPC-157 — Tissue repair support while ipamorelin optimizes systemic GH levels; a natural pairing for injury recovery protocols.
- MOTS-c — Metabolic and mitochondrial support alongside GH optimization for broader performance and longevity goals.
Build Your Personalised Protocol
Ipamorelin is one of many compounds available in the BioStack Generator. Explore growth hormone optimization stacks with CJC-1295 and other secretagogues.